Cyclazodone
NootropicsPreclinicalAlso known as: N-cyclopropylpemoline, Cyclopropylpemoline, Ciclazodona, Cyclazodonum, 2-(cyclopropylimino)-5-phenyl-1,3-oxazolidin-4-one
Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found.
Overview
At A Glance
No receptor binding or transporter data have been published for cyclazodone. It is the N-cyclopropyl derivative of pemoline and belongs to the 4-oxazolidinone stimulant group; pemoline is described as a presynaptic releaser and reuptake blocker of dopamine (PMID: 42188000), and c…
Overview
Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
14461-91-7
Molecular Formula
C12H12N2O2
Molecular Mass
216.24 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
None established by study; the following are mechanism-based or based on the parent compound. The pemoline scaffold carries a documented risk of idiosyncratic liver injury (PMID: 12132793, PMID: 22133982), so pre-existing liver disease or concurrent hepatotoxic drugs are a mechanism-based concern. Formation and clearance in the N-methyl series depends on CYP2A6, so genetic variation in that enzyme or use of CYP2A6 inhibitors would change exposure (PMID: 42188000). No pregnancy, cardiovascular or psychiatric safety data exist.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$54.99
—
1
1
nasal_spray
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Cyclazodone aerosol spray | nasal_spray | 1 aerosol spray● In Stock | $54.99BEST | — | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling Cyclazodone
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
View Full Dosage Guide →
Protocols, calculator & safety for Cyclazodone
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Molecular Weight
216.24 g/mol
Administration
Oral (route used in the published animal metabolism work), Sold on the research chemical market as a solution and as an aerosol spray
CAS Number
14461-91-7
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Cyclazodone used for in research?
Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray.
There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay.
What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently.
Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works.
The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market.
What forms does Cyclazodone come in?
Cyclazodone is available in nasal_spray form.
How much does Cyclazodone cost?
Prices start at $54.99 across 1 verified vendor.
How do I compare Cyclazodone vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.